Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Harvard Bioscience (HBIO) Invested Capital (2016 - 2025)

Historic Invested Capital for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to $48.0 million.

  • Harvard Bioscience's Invested Capital fell 5344.54% to $48.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.0 million, marking a year-over-year decrease of 5344.54%. This contributed to the annual value of $100.3 million for FY2024, which is 851.99% down from last year.
  • As of Q3 2025, Harvard Bioscience's Invested Capital stood at $48.0 million, which was down 5344.54% from $50.6 million recorded in Q2 2025.
  • Harvard Bioscience's Invested Capital's 5-year high stood at $131.7 million during Q4 2021, with a 5-year trough of $48.0 million in Q3 2025.
  • Its 5-year average for Invested Capital is $105.6 million, with a median of $116.8 million in 2023.
  • Its Invested Capital has fluctuated over the past 5 years, first soared by 564.85% in 2021, then tumbled by 5344.54% in 2025.
  • Over the past 5 years, Harvard Bioscience's Invested Capital (Quarter) stood at $131.7 million in 2021, then decreased by 9.63% to $119.0 million in 2022, then dropped by 7.9% to $109.6 million in 2023, then decreased by 8.52% to $100.3 million in 2024, then tumbled by 52.11% to $48.0 million in 2025.
  • Its Invested Capital stands at $48.0 million for Q3 2025, versus $50.6 million for Q2 2025 and $50.8 million for Q1 2025.